Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics


Corcept Therapeutics Incorporated (CORT): $22.99

-0.27 (-1.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CORT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CORT POWR Grades

  • Quality is the dimension where CORT ranks best; there it ranks ahead of 99.81% of US stocks.
  • CORT's strongest trending metric is Sentiment; it's been moving up over the last 177 days.
  • CORT ranks lowest in Growth; there it ranks in the 18th percentile.

CORT Stock Summary

  • With a one year PEG ratio of 297.68, CORCEPT THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 91.47% of US stocks.
  • The ratio of debt to operating expenses for CORCEPT THERAPEUTICS INC is higher than it is for about only 4.82% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.13 for CORCEPT THERAPEUTICS INC; that's greater than it is for merely 10.45% of US stocks.
  • Stocks that are quantitatively similar to CORT, based on their financial statements, market capitalization, and price volatility, are IVAC, VRCA, CLXT, PROF, and MNTS.
  • CORT's SEC filings can be seen here. And to visit CORCEPT THERAPEUTICS INC's official web site, go to www.corcept.com.

CORT Valuation Summary

  • In comparison to the median Healthcare stock, CORT's price/sales ratio is 217.07% higher, now standing at 6.5.
  • CORT's price/earnings ratio has moved up 50.9 over the prior 228 months.

Below are key valuation metrics over time for CORT.

Stock Date P/S P/B P/E EV/EBIT
CORT 2023-01-20 6.5 5.4 22.1 19.9
CORT 2023-01-19 6.4 5.4 21.8 19.7
CORT 2023-01-18 6.4 5.3 21.7 19.6
CORT 2023-01-17 6.2 5.2 21.1 19.1
CORT 2023-01-13 6.1 5.1 20.7 18.7
CORT 2023-01-12 5.9 5.0 20.1 18.2

CORT Growth Metrics

    The 2 year revenue growth rate now stands at 13.53%.
  • The 3 year price growth rate now stands at 86.85%.
  • Its 3 year revenue growth rate is now at 47.14%.
Over the past 33 months, CORT's revenue has gone up $91,138,000.

The table below shows CORT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 397.624 136.362 116.798
2022-06-30 392.027 151.418 112.719
2022-03-31 380.229 177.717 111.844
2021-12-31 365.978 167.892 112.512
2021-09-30 352.891 153.536 106.453
2021-06-30 343.087 135.276 97.607

CORT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CORT has a Quality Grade of A, ranking ahead of 98.86% of graded US stocks.
  • CORT's asset turnover comes in at 0.616 -- ranking 52nd of 681 Pharmaceutical Products stocks.
  • OTIC, ABT, and AVDL are the stocks whose asset turnover ratios are most correlated with CORT.

The table below shows CORT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.616 0.985 0.237
2021-03-31 0.631 0.985 0.248
2020-12-31 0.691 0.984 0.312
2020-09-30 0.754 0.984 0.345
2020-06-30 0.816 0.983 0.413
2020-03-31 0.862 0.982 0.432

CORT Price Target

For more insight on analysts targets of CORT, see our CORT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.25 Average Broker Recommendation 1.75 (Moderate Buy)

CORT Stock Price Chart Interactive Chart >

Price chart for CORT

CORT Price/Volume Stats

Current price $22.99 52-week high $30.14
Prev. close $23.26 52-week low $17.19
Day low $22.98 Volume 416,700
Day high $23.40 Avg. volume 586,305
50-day MA $22.62 Dividend yield N/A
200-day MA $24.35 Market Cap 2.47B

Corcept Therapeutics Incorporated (CORT) Company Bio


Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.


CORT Latest News Stream


Event/Time News Detail
Loading, please wait...

CORT Latest Social Stream


Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about CORCEPT THERAPEUTICS INC that investors may wish to consider to help them evaluate CORT as an investment opportunity.

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by...

Yahoo | January 24, 2023

Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Yahoo | January 17, 2023

Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?

Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 11, 2023

7 Undervalued Biotech Stocks to Buy Before They Boom

While medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy.

Josh Enomoto on InvestorPlace | December 29, 2022

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

It is hard to get excited after looking at Corcept Therapeutics' (NASDAQ:CORT) recent performance, when its stock has...

Yahoo | December 29, 2022

Read More 'CORT' Stories Here

CORT Price Returns

1-mo 13.20%
3-mo -20.28%
6-mo -18.85%
1-year 22.48%
3-year 81.45%
5-year -5.35%
YTD 13.20%
2022 2.58%
2021 -24.31%
2020 116.20%
2019 -9.43%
2018 -26.02%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7646 seconds.